Asterias Bio’s stem cell therapy shows encouraging long-term effect in Phase 1/2 study in spinal cord injury … – Seeking Alpha
|
Asterias Bio’s stem cell therapy shows encouraging long-term effect in Phase 1/2 study in spinal cord injury …
Seeking Alpha Asterias Biotherapeutics (AST +2.7%) announces positive results from the Phase 1/2 SCiStar study assessing AST-OPC1 in patients with subacute motor complete spinal cord injury. Results at month 12 showed 67% of those with AIS-A-categorized injury … |
|
Asterias Bio’s stem cell therapy shows encouraging long-term effect in Phase 1/2 study in spinal cord injury …
Seeking Alpha Asterias Biotherapeutics (AST +2.7%) announces positive results from the Phase 1/2 SCiStar study assessing AST-OPC1 in patients with subacute motor complete spinal cord injury. Results at month 12 showed 67% of those with AIS-A-categorized injury … |
Barron’s |
AveXis gets FDA nod to start pivotal gene therapy trial
BioPharma Dive The infants will be given a once-only dose of the gene therapy AVXS-101, based on one of the doses from the previous Phase 1 trial. The study could readout in 2019. AveXis anticipates starting its study in patients with SMA type 2 in the fourth quarter … AveXis, Inc. (AVXS) – Citigroup Maintains Rating And Updates Price TargetFirst News 24 |
|
Global Synthetic Biology Market share will Increase US$ 38 Billion by 2020
Medgadget (blog) Market Research Engine has published a new report titled as “Synthetic Biology Market (Synthetic DNA, Synthetic Genes, Synthetic Cells, XNA, Chassis Organisms, DNA Synthesis, Oligonucleotide Synthesis) – Global Industry Analysis, Size, Share, Growth, … |
Motherboard en_us |
Scientists Used CRISPR to Edit a Gene That Causes Miscarriages
Motherboard en_us CRISPR, a fairly new gene editing tool, is changing that. While it’s still a long way from preventing miscarriages, researchers have been using the technology to generate new methods of peeking into the genetics behind infertility in hopes of more … We’re nearly ready to use CRISPR to target far more diseases | New …New Scientist Nonviral CRISPR Delivery a SuccessThe Scientist CRISPR Editing in Mice Disrupts Glaucoma-Causing Gene MutationGenomeWeb EurekAlert (press release) –agprofessional.com all 30 news articles » |
|
Study Demonstrates Potential for the Guardant360 Assay® to Predict Which Patients Will Benefit from Immunotherapy
Markets Insider REDWOOD CITY, Calif., Oct. 2, 2017 /PRNewswire/ — Oncologists may get a new tool for identifying which of their cancer patients are most likely to respond to widely prescribed immunotherapies, recent research suggests. In a paper published in Clinical … |